BiotechTube

V503 + GARDASIL

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Papilloma Viral Infection

Conditions

Papilloma Viral Infection

Trial Timeline

Mar 24, 2014 → Apr 22, 2015

NCT ID
NCT02114385

About V503 + GARDASIL

V503 + GARDASIL is a phase 3 stage product being developed by Merck for Papilloma Viral Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02114385. Target conditions include Papilloma Viral Infection.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (4)

NCT IDPhaseStatus
NCT03998254Phase 3Active
NCT02653118Pre-clinicalActive
NCT02114385Phase 3Completed
NCT01304498Phase 3Completed

Competing Products

20 competing products in Papilloma Viral Infection

See all competitors
ProductCompanyStageHype Score
Zopapogene imadenovec (Zopa)PrecigenApproved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
AAVLP-HPV + Placebo2A PharmaPhase 1
25
Lenvatinib + PembrolizumabEisaiPhase 1
33
9vHPV vaccineMerckPhase 3
77
GardasilMerckPre-clinical
23
Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
85
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
77
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
77
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administrationMerckPre-clinical
23
GardasilMerckApproved
85
quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccineMerckPhase 3
77
GardasilMerckPhase 2
52
9vHPV VaccineMerckPhase 3
77
Octavalent HPV with 15 mcg IMX / AAHS + Octavalent HPV with 30 mcg IMX / AAHS + Octavalent HPV with 60 mcg IMX / AAHS + Octavalent HPV with 120 mcg IMX / AAHS + Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)MerckPhase 1
33
9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3
77
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant VaccineMerckPhase 3
77
V501MerckPhase 3
77
V503 + GARDASILMerckPhase 3
77
9vHPV VaccineMerckPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85